As hepatitis A outbreaks, travel-related infections, and foodborne disease investigations continue to drive testing demand in Europe and North America, rapid and reliable serological screening tools are essential. BABIO has introduced its HAV IgG/IgM Rapid Detection Kit (Colloidal Gold Method) to support fast clinical decision-making in laboratories and point-of-care settings.
The HAV IgG/IgM Rapid Detection Kit is a lateral flow immunoassay designed for the qualitative detection of anti-HAV IgM and IgG antibodies in serum, plasma, or whole blood. By differentiating IgM and IgG responses, the test helps clinicians identify acute hepatitis A infection, recent exposure, or past immunity within minutes.
This solution aligns with growing global search demand for terms such as “HAV IgM IgG rapid test,” “hepatitis A antibody test,” “point of care hepatitis A test,” and “colloidal gold immunoassay HAV.”
Using colloidal gold immunochromatography, the test delivers clear visual results in 15 minutes with minimal hands-on time. Its room-temperature storage, long shelf life, and simple workflow make it suitable for hospitals, diagnostic laboratories, travel clinics, public health screening programs, and emergency response settings.
The HAV IgG/IgM Rapid Detection Kit is manufactured by BABIO (Baibo Biotechnology Co., Ltd.), a recognized Chinese manufacturer specializing in in vitro diagnostic reagents and rapid test solutions. BABIO combines standardized production, stable quality control, and global supply capability to meet the evolving needs of international healthcare markets.
🔗 Learn more about BABIO and its diagnostic portfolio at:
https://www.babiocorp.com
#HepatitisATest
#HAVIgGIgM
#RapidDiagnosticTest
#InVitroDiagnostics
#ViralHepatitis
#PointOfCareTesting
#ColloidalGoldAssay
#BABIO